Cytokinetics Director Nancy Wysenski Acquires Stock and Options

Nancy Wysenski, a director of Cytokinetics Inc (CYTK), filed a Form 4 on May 27, 2026, reporting acquisitions of company securities. She acquired 2,851 shares of common stock at $0 per share, bringing her total common stock holdings to 33,917 shares. Additionally, she was granted 4,301 non-qualified stock options with an exercise price of $77.15 per share, expiring on May 26, 2036. The options vest on June 27, 2026. Both transactions were coded as "A" (award/grant) and represent equity compensation awards to the director. The filing was signed by attorney-in-fact John Faurescu on behalf of Ms. Wysenski. These transactions reflect standard equity compensation for corporate directors and demonstrate continued alignment of director interests with shareholder value.